Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are presently covering the stock, ...

Eli Lilly 's blockbuster weight loss drugs, and questions about its valuation. Then, Ricky continues his conversation with ...

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock face investor scrutiny as RFK Jr. takes the leadership of HHS. Read more ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.